Syngene will provide fully integrated, end-to-end services for antibody-drug conjugates
Syngene International, a global contract research, development and manufacturing organisation (CRDMO), is set to add a GMP bioconjugation suite at its commercial biologics facility in Bengaluru. With this new capability, Syngene will provide fully integrated, end-to-end services for antibody-drug conjugates (ADCs)- from discovery through to GMP manufacturing.
The OEB-5-rated suite will advance ADC development timelines by allowing Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, accompanying Syngenes’ existing commercial capabilities in payload and linker manufacturing.
The conjugation is expected to be operational within this financial year and will support a variety of advanced conjugates and related modalities. These services are further reinforced by collacted analytical and bioanalytical capabilities to ensure seamless integration across the development lifecycle.
Alex Del Priore, head of LM CDMO, Syngene International, said, “The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays. By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing.”
Leveraging a decade of experience in ADC discovery, along with expertise in handling high-potency payloads, linkers, and mAbs across well-established, GMP-compliant facilities, Syngene is developing its capabilities to support clinical programs and plans to conceive commercial-scale capabilities in the future.
The laboratories will also provide process development, analytical characterisation, and scale-up for both early- and late-stage programs. This addition aims to enhance Syngene’s ability to serve biotech and biopharma clients pursuing agile, science-driven partners for their ADC programs.
